<?xml version="1.0" encoding="UTF-8"?>
<search_results count="1046">
  <query>SEARCH[STUDY] ( Crohn's Disease [STUDY:ALL-FIELDS] )</query>
  <clinical_study>
    <order>501</order>
    <score>0.86622</score>
    <nct_id>NCT01338740</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01338740</url>
    <title>Switching From Adalimumab to Infliximab</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Adalimumab and Infliximab</intervention_summary>
    <last_changed>December 4, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>502</order>
    <score>0.86617</score>
    <nct_id>NCT00936585</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00936585</url>
    <title>NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Colitis; Crohn's Disease; Inflammatory Bowel Disease</condition_summary>
    <intervention_summary>Other: Immunologic Monitoring</intervention_summary>
    <last_changed>December 7, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>503</order>
    <score>0.8647</score>
    <nct_id>NCT01241058</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01241058</url>
    <title>Registry of Pediatric Patients Diagnosed With Crohn's Disease in Belgium</title>
    <status open="N">Completed</status>
    <condition_summary>Description of Disease Course, Disease Fenotype, Medication, Safety, Analysis for Possible Associations</condition_summary>
    <last_changed>January 17, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>504</order>
    <score>0.863</score>
    <nct_id>NCT01372969</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01372969</url>
    <title>Study to Assess the Safety and Efficacy of Expanded Allogenic Adipose-derived Stem Cells (eASCs) (Cx601), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease.</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Anal Fistula</condition_summary>
    <intervention_summary>Drug: Cx601</intervention_summary>
    <last_changed>June 13, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>505</order>
    <score>0.86227</score>
    <nct_id>NCT02743806</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02743806</url>
    <title>Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Colitis, Ulcerative; Crohn Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab</intervention_summary>
    <last_changed>May 11, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>506</order>
    <score>0.86223</score>
    <nct_id>NCT00004423</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00004423</url>
    <title>Controlled Trial of 4-Aminosalicylic Acid in Patients With Small Bowel Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: -aminosalicylic acid</intervention_summary>
    <last_changed>March 24, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>507</order>
    <score>0.86217</score>
    <nct_id>NCT01783106</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01783106</url>
    <title>Antibiotics and Hydroxychloroquine in Crohn's</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Ciprofloxacin; Drug: Doxycycline; Drug: Hydroxychloroquine; Drug: Budesonide</intervention_summary>
    <last_changed>June 26, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>508</order>
    <score>0.8621</score>
    <nct_id>NCT00741910</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00741910</url>
    <title>Extension Study of Semapimod 60 mg IV x 3 Days</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Semapimod</intervention_summary>
    <last_changed>August 22, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>509</order>
    <score>0.86194</score>
    <nct_id>NCT02326155</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02326155</url>
    <title>To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis</condition_summary>
    <last_changed>June 5, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>510</order>
    <score>0.8619</score>
    <nct_id>NCT01881464</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01881464</url>
    <title>Anti TNF α Improves Endothelial Dysfunction in IBD Patients</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Device: Endopath from Itamar medical - FDA approved device.; Drug: Anti TNF Alfa.</intervention_summary>
    <last_changed>May 15, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>511</order>
    <score>0.86178</score>
    <nct_id>NCT03104413</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03104413</url>
    <title>A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: risankizumab IV; Drug: placebo for risankizumab IV; Drug: risankizumab SC</intervention_summary>
    <last_changed>April 4, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>512</order>
    <score>0.86146</score>
    <nct_id>NCT02878395</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02878395</url>
    <title>Genomic/Epigenomic Biomarkers of Deregulation of Immune System in Inflammatory Bowel Diseases</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Procedure: Ileocolic resection</intervention_summary>
    <last_changed>August 22, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>513</order>
    <score>0.86126</score>
    <nct_id>NCT00783575</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00783575</url>
    <title>Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis; Inflammatory Bowel Disease</condition_summary>
    <last_changed>August 21, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>514</order>
    <score>0.86073</score>
    <nct_id>NCT02247258</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02247258</url>
    <title>Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn Disease; Recurrence; Azathioprine; Prevention</condition_summary>
    <intervention_summary>Drug: Azathioprine; Drug: Azathioprine in case of endoscopic recurrence; Procedure: Ileocolonoscopy; Procedure: Small bowel follow trough</intervention_summary>
    <last_changed>May 28, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>515</order>
    <score>0.86057</score>
    <nct_id>NCT02943538</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02943538</url>
    <title>Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Colitis, Ulcerative</condition_summary>
    <intervention_summary>Device: Telemedicine; Device: Telephone; Other: Conventional care</intervention_summary>
    <last_changed>January 16, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>516</order>
    <score>0.86012</score>
    <nct_id>NCT00619489</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00619489</url>
    <title>Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: vedolizumab</intervention_summary>
    <last_changed>June 19, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>517</order>
    <score>0.86002</score>
    <nct_id>NCT00132899</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00132899</url>
    <title>COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Methotrexate; Drug: Placebo</intervention_summary>
    <last_changed>December 10, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>518</order>
    <score>0.85978</score>
    <nct_id>NCT01369329</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01369329</url>
    <title>A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease</condition_summary>
    <intervention_summary>Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo</intervention_summary>
    <last_changed>October 14, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>519</order>
    <score>0.85957</score>
    <nct_id>NCT03196427</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03196427</url>
    <title>Long-term Safety With Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab</intervention_summary>
    <last_changed>June 22, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>520</order>
    <score>0.85892</score>
    <nct_id>NCT01698307</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01698307</url>
    <title>Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy</title>
    <status open="N">Enrolling by invitation</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Enhanced Treatment Algorithm; Other: Conventional Step-care Algorithm</intervention_summary>
    <last_changed>July 12, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>521</order>
    <score>0.85861</score>
    <nct_id>NCT00004941</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00004941</url>
    <title>Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: monoclonal antibody cA2</intervention_summary>
    <last_changed>March 24, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>522</order>
    <score>0.85847</score>
    <nct_id>NCT02532738</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02532738</url>
    <title>The Efficiency of MSC in Refractory Crohn's Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Routine Treatment of CD; Biological: MSC treatment 01; Biological: MSC treatment 02; Other: NS</intervention_summary>
    <last_changed>August 25, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>523</order>
    <score>0.85833</score>
    <nct_id>NCT01570348</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01570348</url>
    <title>Crohn's Allogeneic Transplant Study</title>
    <status open="N">Suspended</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Procedure: Allogeneic Bone Marrow Transplantation; Drug: Cyclophosphamide; Drug: Fludarabine Phosphate; Other: Laboratory Biomarker Analysis; Drug: Mycophenolate Mofetil; Drug: Mycophenolic Acid; Other: Quality-of-Life Assessment; Drug: Tacrolimus; Radiation: Total-Body Irradiation</intervention_summary>
    <last_changed>August 2, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>524</order>
    <score>0.85796</score>
    <nct_id>NCT01369342</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01369342</url>
    <title>A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis</condition_summary>
    <intervention_summary>Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg</intervention_summary>
    <last_changed>November 9, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>525</order>
    <score>0.85773</score>
    <nct_id>NCT02956538</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02956538</url>
    <title>Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Thalidomide; Drug: placebo(for thalidomide)</intervention_summary>
    <last_changed>November 3, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>526</order>
    <score>0.85717</score>
    <nct_id>NCT01352221</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01352221</url>
    <title>Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)</title>
    <status open="N">Completed</status>
    <condition_summary>Iron Deficiency Anaemia; Inflammatory Bowel Disease; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: ST10-021; Drug: Placebo Comparator</intervention_summary>
    <last_changed>August 30, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>527</order>
    <score>0.85655</score>
    <nct_id>NCT01768858</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01768858</url>
    <title>Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Rheumatoid Arthritis; Ankylosing Spondylitis; Psoriatic Arthritis; Crohn´s Disease; Ulcerative Colitis; Plaque Psoriasis</condition_summary>
    <last_changed>July 17, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>528</order>
    <score>0.8565</score>
    <nct_id>NCT02199561</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02199561</url>
    <title>Fecal Microbiota Transplantation (FMT) in the Management of Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Fecal Microbiota Transplant</intervention_summary>
    <last_changed>December 13, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>529</order>
    <score>0.85645</score>
    <nct_id>NCT02425111</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02425111</url>
    <title>Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab</intervention_summary>
    <last_changed>July 28, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>530</order>
    <score>0.85627</score>
    <nct_id>NCT01503099</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01503099</url>
    <title>Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Intestinal Tuberculosis; Pulmonary Tuberculosis; Crohn's Disease</condition_summary>
    <last_changed>December 30, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>531</order>
    <score>0.856</score>
    <nct_id>NCT02349594</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02349594</url>
    <title>Immune Modulation by Parenteral Fish Oil in Patients With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Omegaven 10%; Drug: Intralipid 20%</intervention_summary>
    <last_changed>November 9, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>532</order>
    <score>0.85578</score>
    <nct_id>NCT00376649</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00376649</url>
    <title>Development of Workshop for Lifestyle Changing for Crohn's Disease Patients and Its Affect on the Disease's Indexes</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Behavioral: lifestyle changing workshop</intervention_summary>
    <last_changed>September 20, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>533</order>
    <score>0.85543</score>
    <nct_id>NCT00792740</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00792740</url>
    <title>Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: ITF2357; Drug: Placebo capsules</intervention_summary>
    <last_changed>February 1, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>534</order>
    <score>0.8547</score>
    <nct_id>NCT00783692</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00783692</url>
    <title>Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: vedolizumab; Other: Placebo</intervention_summary>
    <last_changed>June 19, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>535</order>
    <score>0.85444</score>
    <nct_id>NCT01666626</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01666626</url>
    <title>Ultrasound Stiffness Imaging in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Ultrasound; Intestinal Fibrosis; Shear Wave Imaging; Acoustic Radiation Force Impulse</condition_summary>
    <intervention_summary>Procedure: Ultrasound stiffness imaging</intervention_summary>
    <last_changed>July 29, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>536</order>
    <score>0.85437</score>
    <nct_id>NCT02580864</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02580864</url>
    <title>Bologna IBD Markers</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <last_changed>November 29, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>537</order>
    <score>0.85428</score>
    <nct_id>NCT02417974</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02417974</url>
    <title>Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Fecal Microbiota Transplant (FMT)</intervention_summary>
    <last_changed>March 2, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>538</order>
    <score>0.85412</score>
    <nct_id>NCT02513459</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02513459</url>
    <title>A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab) in Patients With Moderately to Severely Active Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: ABBV-066; Drug: ABBV-066</intervention_summary>
    <last_changed>July 7, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>539</order>
    <score>0.85357</score>
    <nct_id>NCT03009396</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03009396</url>
    <title>Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: RHB-104</intervention_summary>
    <last_changed>July 20, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>540</order>
    <score>0.85345</score>
    <nct_id>NCT01187459</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01187459</url>
    <title>Vitamin D in Pediatric Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Vitamin D Deficiency</condition_summary>
    <intervention_summary>Dietary Supplement: Vitamin D; Dietary Supplement: Vitamin D</intervention_summary>
    <last_changed>February 10, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>541</order>
    <score>0.85317</score>
    <nct_id>NCT01203254</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01203254</url>
    <title>Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohns Disease; Bile Acid Malabsorption</condition_summary>
    <intervention_summary>Drug: Colesevelam; Drug: Placebo</intervention_summary>
    <last_changed>April 17, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>542</order>
    <score>0.85304</score>
    <nct_id>NCT02842450</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02842450</url>
    <title>Study of Photographs of Interest in Training to Obtain Good Reproducibility of the Diagnosis of Perianal Lesions of Crohn's Disease Inspection in Internal Gastroenterology</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn</condition_summary>
    <intervention_summary>Device: Photos + definitions; Other: definitions only</intervention_summary>
    <last_changed>July 21, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>543</order>
    <score>0.85226</score>
    <nct_id>NCT00723047</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00723047</url>
    <title>Fibrin Glue for Perianal Fistulas in Crohn's Disease: a Randomized Controlled Trial</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Procedure: Fibrin glue injection in fistula</intervention_summary>
    <last_changed>September 2, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>544</order>
    <score>0.85073</score>
    <nct_id>NCT00440817</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00440817</url>
    <title>An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.</title>
    <status open="N">Completed</status>
    <condition_summary>Lymphoma</condition_summary>
    <intervention_summary>Other: No intervention</intervention_summary>
    <last_changed>April 9, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>545</order>
    <score>0.85051</score>
    <nct_id>NCT00354367</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00354367</url>
    <title>Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Certolizumab pegol</intervention_summary>
    <last_changed>May 25, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>546</order>
    <score>0.85011</score>
    <nct_id>NCT00245505</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00245505</url>
    <title>The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active &quot;Drug: Crohn's Disease&quot;</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Mesalazine (Mesalamine)</intervention_summary>
    <last_changed>March 9, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>547</order>
    <score>0.84989</score>
    <nct_id>NCT00736983</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00736983</url>
    <title>Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease With Perianal Fistulas</condition_summary>
    <intervention_summary>Drug: adalimumab; Drug: ciprofloxacin</intervention_summary>
    <last_changed>April 16, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>548</order>
    <score>0.84942</score>
    <nct_id>NCT00630643</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00630643</url>
    <title>NI-0401 in Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Moderate to Severe Crohn's Disease</condition_summary>
    <intervention_summary>Biological: NI-0401 (anti-CD3 mAB); Drug: Placebo</intervention_summary>
    <last_changed>March 6, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>549</order>
    <score>0.84924</score>
    <nct_id>NCT03077412</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03077412</url>
    <title>Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Fistulizing Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Filgotinib; Drug: Placebo to match filgotinib</intervention_summary>
    <last_changed>July 25, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>550</order>
    <score>0.84916</score>
    <nct_id>NCT01942720</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01942720</url>
    <title>Monitoring Disease Activity Using Video Capsule Endoscopy (VCE) in Crohn's Disease (CD) Subjects</title>
    <status open="N">Completed</status>
    <condition_summary>Known Crohn Disease Subjects</condition_summary>
    <intervention_summary>Device: Capsule endoscopy and Ileocolonoscopy tests</intervention_summary>
    <last_changed>April 30, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>551</order>
    <score>0.84792</score>
    <nct_id>NCT01442363</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01442363</url>
    <title>A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Perianal Crohn's Disease</condition_summary>
    <intervention_summary>Drug: BLI-1300 low dose; Drug: BLI-1300 high dose; Drug: placebo</intervention_summary>
    <last_changed>January 26, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>552</order>
    <score>0.8467</score>
    <nct_id>NCT01864616</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01864616</url>
    <title>The Impact of Vitamin D on Disease Activity in Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn Disease,</condition_summary>
    <intervention_summary>Dietary Supplement: Vitamin D3</intervention_summary>
    <last_changed>May 24, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>553</order>
    <score>0.84665</score>
    <nct_id>NCT00510978</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00510978</url>
    <title>Probiotics in GastroIntestinal Disorders</title>
    <status open="N">Unknown status</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Bifidobacterium infantis 35624; Biological: Lactobacillus salivarius UCC118; Biological: Placebo</intervention_summary>
    <last_changed>June 13, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>554</order>
    <score>0.84573</score>
    <nct_id>NCT03000296</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03000296</url>
    <title>Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease; Inflammatory Bowel Diseases; Gastroenteritis</condition_summary>
    <intervention_summary>Procedure: Autologous Hematopoietic Stem Cell Transplantation</intervention_summary>
    <last_changed>December 21, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>555</order>
    <score>0.84533</score>
    <nct_id>NCT01947010</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01947010</url>
    <title>Pneumococcal Vaccination of Crohn Patients</title>
    <status open="N">Completed</status>
    <condition_summary>Crohns Disease</condition_summary>
    <intervention_summary>Biological: Prevenar 13; Biological: Pneumovax</intervention_summary>
    <last_changed>February 6, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>556</order>
    <score>0.84346</score>
    <nct_id>NCT02872506</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02872506</url>
    <title>Comparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical Resection</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Quality of Life</condition_summary>
    <intervention_summary>Drug: Anti TNF; Procedure: ileocecal resection</intervention_summary>
    <last_changed>June 6, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>557</order>
    <score>0.84222</score>
    <nct_id>NCT01792388</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01792388</url>
    <title>Vitd and Barrier Function in IBD</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Dietary Supplement: Vitamin D; Dietary Supplement: Soya Bean oil</intervention_summary>
    <last_changed>July 21, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>558</order>
    <score>0.8413</score>
    <nct_id>NCT01880307</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01880307</url>
    <title>Infliximab Top-down in Pediatric Crohn</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Azathioprine; Drug: Infliximab; Drug: Prednisolon</intervention_summary>
    <last_changed>July 1, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>559</order>
    <score>0.83739</score>
    <nct_id>NCT01823029</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01823029</url>
    <title>Oxidative Stress and Inflammation Caused by Intravenous Iron in Crohn's Disease Patients With Iron Deficiency Anemia</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: erythropoietin; Drug: enteral nutrition.; Drug: injection of iron</intervention_summary>
    <last_changed>November 26, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>560</order>
    <score>0.83512</score>
    <nct_id>NCT01369355</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01369355</url>
    <title>A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease; Colitis; IBD; Inflammatory Bowel Disease</condition_summary>
    <intervention_summary>Drug: Placebo SC; Drug: Placebo IV; Drug: Ustekinumab 90 mg SC q8w; Drug: Ustekinumab 130 mg IV; Drug: Ustekinumab 90 mg SC q12w</intervention_summary>
    <last_changed>April 5, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>561</order>
    <score>0.83415</score>
    <nct_id>NCT00138879</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00138879</url>
    <title>Citrulline: A Plasmatic Marker to Assess and Monitor Small Bowel Crohn's Disease Patients</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Short Bowel Syndrome; Malabsorption Syndromes; Celiac Disease</condition_summary>
    <last_changed>December 14, 2005</last_changed>
  </clinical_study>
  <clinical_study>
    <order>562</order>
    <score>0.83367</score>
    <nct_id>NCT00815061</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00815061</url>
    <title>Epidemiology of Ulcerative Colitis and Crohn's Disease in Non Jewish Israel Population</title>
    <status open="N">Unknown status</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease</condition_summary>
    <last_changed>December 2, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>563</order>
    <score>0.8331</score>
    <nct_id>NCT01887548</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01887548</url>
    <title>Personality Traits and Its Impact on Quality of Life and Clinical Outcome Evaluation in Crohn's Patients</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Personality Traits Questionnaires</intervention_summary>
    <last_changed>June 24, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>564</order>
    <score>0.83266</score>
    <nct_id>NCT00454545</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00454545</url>
    <title>Atorvastatin in Moderate Active Crohns Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohns Disease</condition_summary>
    <intervention_summary>Drug: Atorvastatin</intervention_summary>
    <last_changed>October 18, 2007</last_changed>
  </clinical_study>
  <clinical_study>
    <order>565</order>
    <score>0.83265</score>
    <nct_id>NCT02245594</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02245594</url>
    <title>GI Symptoms and Sleep Disturbances in Patients With Quiescent Crohns Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease; Inflammatory Bowel Disease; Sleep Disturbances</condition_summary>
    <last_changed>September 17, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>566</order>
    <score>0.83165</score>
    <nct_id>NCT01674413</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01674413</url>
    <title>Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Adalimumab; Drug: Adalimumab PRN; Drug: Placebo</intervention_summary>
    <last_changed>May 23, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>567</order>
    <score>0.83059</score>
    <nct_id>NCT03185000</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03185000</url>
    <title>Treg Immunotherapy in Crohn's Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: TR004 (Treg immunotherapy); Other: Placebo</intervention_summary>
    <last_changed>June 12, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>568</order>
    <score>0.83049</score>
    <nct_id>NCT00072943</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00072943</url>
    <title>A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Colitis; Intestinal Disease; Gastrointestinal Disease; Digestive System Disease</condition_summary>
    <intervention_summary>Drug: anti-Interferon-gamma monoclonal antibody</intervention_summary>
    <last_changed>March 9, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>569</order>
    <score>0.82857</score>
    <nct_id>NCT02522169</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02522169</url>
    <title>TOPIT; Trough Level Optimized Pediatric Inflammatory Bowel Disease Therapy: A Multicenter Study Comparing Effectiveness of Trough Level Optimized Infliximab Maintenance Therapy With Standard Dosing Regimen of Pediatric Patients With Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Pediatric Crohns Disease</condition_summary>
    <intervention_summary>Drug: Infliximab</intervention_summary>
    <last_changed>August 12, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>570</order>
    <score>0.82834</score>
    <nct_id>NCT00035503</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00035503</url>
    <title>Multicenter Trial For Patients With Acute Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: etiprednol dicloacetate</intervention_summary>
    <last_changed>February 20, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>571</order>
    <score>0.82442</score>
    <nct_id>NCT03056664</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03056664</url>
    <title>The Role of MSC in the Treatment of Fistulas in Patients With Perianal Crohn's Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn's Disease; Fistula</condition_summary>
    <intervention_summary>Procedure: Routine drainage surgery; Biological: MSC injection 01; Biological: MSC injection 02; Other: placebo</intervention_summary>
    <last_changed>February 14, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>572</order>
    <score>0.82035</score>
    <nct_id>NCT00653094</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00653094</url>
    <title>An Open Label, Prospective, One Arm, Feasibility, Study for The Use of Halevy Kit for the Treatment of Perianal Fistulas in Patients With Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn Disease; Fistula</condition_summary>
    <intervention_summary>Device: Halevy kit</intervention_summary>
    <last_changed>April 3, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>573</order>
    <score>0.81714</score>
    <nct_id>NCT00940576</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00940576</url>
    <title>Dietetic Efficacy of Mare's Milk for Patients With Chronic Inflammatory Bowel Diseases</title>
    <status open="N">Completed</status>
    <condition_summary>Ulcerative Colitis; Crohns Disease</condition_summary>
    <intervention_summary>Dietary Supplement: mare´s milk; Other: placebo drink</intervention_summary>
    <last_changed>May 5, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>574</order>
    <score>0.81695</score>
    <nct_id>NCT03176875</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03176875</url>
    <title>Comparison of Partial and Exclusive Enteral Nutrition in the Treatment of Active Childhood-onset Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Adolescent; Child; Diet; Crohn Disease; Enteral Nutrition; Remission</condition_summary>
    <intervention_summary>Other: ALICALM (75% of daily caloric requirements); Other: ALICALM (100% of daily caloric requirements)</intervention_summary>
    <last_changed>June 6, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>575</order>
    <score>0.81656</score>
    <nct_id>NCT02777034</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02777034</url>
    <title>Laparoscopy Combined With Enhanced Recovery Pathway</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: ER; Other: UR</intervention_summary>
    <last_changed>May 18, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>576</order>
    <score>0.81592</score>
    <nct_id>NCT00686374</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00686374</url>
    <title>Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Adalimumab</intervention_summary>
    <last_changed>April 19, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>577</order>
    <score>0.81591</score>
    <nct_id>NCT03052465</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03052465</url>
    <title>Magnetic Resonance Imaging of Motility in Crohn's 2</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Other: Test soup meal feeding intervention</intervention_summary>
    <last_changed>February 13, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>578</order>
    <score>0.81376</score>
    <nct_id>NCT02274714</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02274714</url>
    <title>Dysmenorrhea in Women With Crohn's Disease and Ulcerative Colitis</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis</condition_summary>
    <intervention_summary>Other: Questionnaire Only</intervention_summary>
    <last_changed>January 20, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>579</order>
    <score>0.81338</score>
    <nct_id>NCT03012542</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03012542</url>
    <title>Diet as Essential Therapy (DIET) for Inflammatory Bowel Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Dietary Supplement: Diet 1; Dietary Supplement: Diet 2</intervention_summary>
    <last_changed>March 7, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>580</order>
    <score>0.81196</score>
    <nct_id>NCT00655135</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00655135</url>
    <title>Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: LDP-02; Drug: Placebo</intervention_summary>
    <last_changed>April 8, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>581</order>
    <score>0.81164</score>
    <nct_id>NCT01387594</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01387594</url>
    <title>Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Ileitis; Ileo-colonic and Colonic Crohn's Disease; Granulomatous Colitis; Regional Enteritis; Ulcerative Colitis</condition_summary>
    <intervention_summary>Procedure: lumbar puncture; Drug: lumbar puncture</intervention_summary>
    <last_changed>May 4, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>582</order>
    <score>0.81032</score>
    <nct_id>NCT01828190</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01828190</url>
    <title>The Influence of Hyperbaric Oxygen in Patients With Perianal Crohn's Disease Already Treated With TNF Alpha Blockers Treated With TNF Alpha Blockers</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease; Perianal Fistulas</condition_summary>
    <intervention_summary>Other: Hyperbaric oxygen</intervention_summary>
    <last_changed>April 8, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>583</order>
    <score>0.80924</score>
    <nct_id>NCT00511329</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00511329</url>
    <title>Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Arthritis, Juvenile Rheumatoid; Crohn Disease</condition_summary>
    <intervention_summary>Drug: somatropin [rDNA origin] for injection</intervention_summary>
    <last_changed>May 14, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>584</order>
    <score>0.80881</score>
    <nct_id>NCT02597829</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02597829</url>
    <title>Does Clinical Response Correlate With Serum Certolizumab Levels?</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Certolizumab Pegol</intervention_summary>
    <last_changed>November 4, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>585</order>
    <score>0.80703</score>
    <nct_id>NCT00790933</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00790933</url>
    <title>An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab</intervention_summary>
    <last_changed>February 17, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>586</order>
    <score>0.80689</score>
    <nct_id>NCT00989560</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00989560</url>
    <title>Post-operative Crohn's Endoscopic Recurrence Study</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Procedure: endoscopy</intervention_summary>
    <last_changed>January 10, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>587</order>
    <score>0.80419</score>
    <nct_id>NCT02488005</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02488005</url>
    <title>The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Device: Ultrasound</intervention_summary>
    <last_changed>October 7, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>588</order>
    <score>0.80385</score>
    <nct_id>NCT02913508</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02913508</url>
    <title>Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab intravenous injection; Drug: Vedolizumab subcutaneous injection</intervention_summary>
    <last_changed>September 22, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>589</order>
    <score>0.80315</score>
    <nct_id>NCT00972218</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00972218</url>
    <title>Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Spondyloarthritis; Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Adalimumab</intervention_summary>
    <last_changed>September 14, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>590</order>
    <score>0.8026</score>
    <nct_id>NCT02856763</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02856763</url>
    <title>Predictive Factors of ANTI-TNF Response in Luminal Crohn's Disease Complicated by Abscess</title>
    <status open="Y">Recruiting</status>
    <condition_summary>CD</condition_summary>
    <last_changed>August 4, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>591</order>
    <score>0.79861</score>
    <nct_id>NCT03183661</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03183661</url>
    <title>A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial</title>
    <status open="N">Enrolling by invitation</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Biological: ALLO-ASC-CD</intervention_summary>
    <last_changed>June 8, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>592</order>
    <score>0.79817</score>
    <nct_id>NCT01298492</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01298492</url>
    <title>A Study To Monitor Long-Term Treatment With PF-00547659</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: PF-00547659</intervention_summary>
    <last_changed>August 30, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>593</order>
    <score>0.79754</score>
    <nct_id>NCT02578238</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02578238</url>
    <title>Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the &quot;New-Drug Re-examination&quot;</title>
    <status open="N">Completed</status>
    <condition_summary>Pediatric Crohn's Disease</condition_summary>
    <last_changed>June 1, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>594</order>
    <score>0.79667</score>
    <nct_id>NCT01926730</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01926730</url>
    <title>Food and Crohn's Exacerbation Study (FACES)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Restriction diet</intervention_summary>
    <last_changed>February 13, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>595</order>
    <score>0.796</score>
    <nct_id>NCT01169207</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01169207</url>
    <title>Johns Hopkins Crohn's Disease and Ulcerative Colitis Study</title>
    <status open="N">Unknown status</status>
    <condition_summary>Inflammatory Bowel Disease</condition_summary>
    <last_changed>July 6, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>596</order>
    <score>0.79332</score>
    <nct_id>NCT01793376</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01793376</url>
    <title>Development of Niv Score of Capsule Endoscopy in Patients With Crohn's (CECDAIic)</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <last_changed>March 11, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>597</order>
    <score>0.79274</score>
    <nct_id>NCT01540292</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01540292</url>
    <title>Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Mesenchymal Stem Cells (MSC)</intervention_summary>
    <last_changed>January 17, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>598</order>
    <score>0.79253</score>
    <nct_id>NCT00237055</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00237055</url>
    <title>Infectious Agents in Pediatric Crohn's</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Inflammatory Bowel Disease</condition_summary>
    <last_changed>March 17, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>599</order>
    <score>0.79025</score>
    <nct_id>NCT00774969</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00774969</url>
    <title>Evaluation of the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Perianal Crohns'</condition_summary>
    <intervention_summary>Drug: Metronidazole</intervention_summary>
    <last_changed>October 16, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>600</order>
    <score>0.78693</score>
    <nct_id>NCT01629628</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01629628</url>
    <title>Adalimumab for the Management of Post-operative Crohn's Disease (CD)</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Adalimumab; Drug: 6 Mercaptopurine</intervention_summary>
    <last_changed>June 25, 2012</last_changed>
  </clinical_study>
</search_results>
